Genolution Inc. (225220) - Total Liabilities
Based on the latest financial reports, Genolution Inc. (225220) has total liabilities worth ₩26.44 Billion KRW (≈ $17.92 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genolution Inc. - Total Liabilities Trend (2016–2024)
This chart illustrates how Genolution Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Genolution Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Genolution Inc. Competitors by Total Liabilities
The table below lists competitors of Genolution Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nexen Tire Prf 1
KO:002355
|
Korea | ₩2.95 Trillion |
|
MMC Sanayi ve Ticari Yatirimlar AS
IS:MMCAS
|
Turkey | TL10.52 Million |
|
Paragon Banking Group PLC
LSE:PAG
|
UK | GBX17.76 Billion |
|
IRIDEX Corporation
NASDAQ:IRIX
|
USA | $24.23 Million |
|
Benalec Holdings Bhd
KLSE:5190
|
Malaysia | RM241.61 Million |
|
Neometals Ltd
AU:NMT
|
Australia | AU$8.74 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Genolution Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Genolution Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genolution Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genolution Inc. (2016–2024)
The table below shows the annual total liabilities of Genolution Inc. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩26.16 Billion ≈ $17.73 Million |
+0.68% |
| 2023-12-31 | ₩25.99 Billion ≈ $17.61 Million |
+31.55% |
| 2022-12-31 | ₩19.75 Billion ≈ $13.39 Million |
+55.08% |
| 2021-12-31 | ₩12.74 Billion ≈ $8.63 Million |
-43.34% |
| 2020-12-31 | ₩22.48 Billion ≈ $15.24 Million |
+108.37% |
| 2019-12-31 | ₩10.79 Billion ≈ $7.31 Million |
+32.26% |
| 2018-12-31 | ₩8.16 Billion ≈ $5.53 Million |
+1058.74% |
| 2017-12-31 | ₩704.01 Million ≈ $477.10K |
+23.38% |
| 2016-12-31 | ₩570.62 Million ≈ $386.70K |
-- |
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more